Strata Skin Sciences Sales Decline

Strata Skin Sciences (NASDAQ:SSKN), a medical technology firm specializing in dermatology devices, reported its second quarter 2025 earnings on August 13, 2025. The company reported GAAP revenue of $7.7 million, missing analyst expectations of $8.56 million and down from $8.4 million in Q2 2024. GAAP earnings per share were negative $0.60, below estimates for a negative $0.29 result, and reflecting a significant deterioration from negative $0.03 per share in Q2 2024. Results highlighted operational weakness, with both recurring and equipment revenue dropping, while gross profit and profitability measures also declined. Although the quarter included a major reimbursement win that could increase XTRAC’s long-term market opportunity, the short-term financial performance fell short of expectations. Source: Analyst estimates for the quarter provided by FactSet. Strata Skin Sciences is a medical device company serving dermatologists and clinics worldwide. Its key products include excimer laser systems (XTRAC and Pharos), lamp-based phototherapy systems (VTRAC), and the TheraClearX acne treatment system. These technologies are used to treat common skin conditions such as psoriasis, vitiligo, and acne.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool